Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1682940 | 0.98 | TYMP (0.59) | TYMP | |
| SCHEMBL6572715 | 0.85 | TYMP (0.57) | TYMP | |
| Hydrochloric Acid SCHEMBL6572739 | 0.82 | TYMP (0.54) | TYMP | |
| Hydrochloric Acid SCHEMBL1691079 | 0.80 | TYMP (0.51) | TYMP | |
| SCHEMBL6571732 | 0.74 | TYMP (0.53) | TYMP | |
| Hydrochloric Acid SCHEMBL1682955 | 0.72 | TYMP (1.00) | TYMP | |
| SCHEMBL6571658 | 0.71 | TYMP (0.71) | TYMP | |
| SCHEMBL20599962 | 0.70 | TYMP (0.59) | TYMP | |
| Hydrochloric Acid SCHEMBL1691080 | 0.70 | TYMP (0.56) | TYMP | |
| SCHEMBL6060121 | 0.68 | TYMP (0.52) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | claimed |
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | disclosed |